TokenPost
Cover art for Vivos Targets $3.8 Million Revenue Lift

Vivos Targets $3.8 Million Revenue Lift

Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027.

Nov 17, 2026

3 cards · 50s · tap to begin

From · · 50s

Vivos Targets $3.8 Million Revenue Lift

Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027.

In brief

Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027. Vivos Therapeutics targets $3.8 million in additional annual revenue from payer contract renegotiations to achieve positive operating cash flow by early 2027. Originally reported by TokenPost.

Vivos Therapeutics Revenue Target

An unsigned folder rests on an empty clinic reception counter / TokenPost.ai

Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract renegotiations to achieve positive operating cash flow by early 2027.

Financial Risks

Management reported $200,000 in cash and warned of substantial doubt about Vivos’ ability to continue as a going concern.

Nasdaq Listing Risk

Vivos remains out of compliance with Nasdaq’s $1 minimum bid-price requirement, risking delisting if the closing bid stays at or below $0.10 for 10 straight business days.

The headline

Vivos Therapeutics targets $3.8 million in additional annual revenue from payer contract renegotiations to achieve positive operating cash flow by early 2027.

Read the original on TokenPost

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on vivos therapeutics and related topics.